Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Envoy Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Envoy Medical's regulatory disclosures and financial reporting.
Envoy Medical, Inc. filed an 8-K reporting the satisfaction of promissory notes between the company and GAT Funding, LLC, effective August 25, 2025. The filing references termination of a material definitive agreement and notes related disclosure items for director or officer changes without providing specific names or details in the text provided.
The filing lists the company's securities (Class A Common Stock, COCH; Redeemable Warrants, COCHW) and attaches a press release dated August 26, 2025. The document is signed by Brent T. Lucas, Chief Executive Officer.
Alta Partners LLC filed a Schedule 13G reporting beneficial ownership of 1,944,139 shares of Envoy Medical, Inc. Class A common stock (shares issuable upon exercise of warrants), representing 8.25% of the class. Alta Partners reports sole voting and dispositive power over these shares and certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Envoy Medical (NASDAQ:COCH) announced the appointment of Robert Potashnick as Interim Chief Financial Officer, effective June 23, 2025. Potashnick, 45, will serve as the company's principal financial officer and principal accounting officer through his consulting entity Oasis Business Consulting LLC. He brings significant experience from previous CFO roles at Flutterbee Education Group and FOXO Technologies, along with positions at UnitedHealth Group and PricewaterhouseCoopers LLP. The appointment is structured through a Consulting Agreement on a fractional consultant basis.